Stay up to date with the latest breaking news, analysis and commentary on Mirae Asset Sharekhan. Find live updates, exchanges, stock news, earning news and more.
Jindal Steel: The company has completed the 6mtpa expansion at Angul, taking its crude steel capacity in Angul to 12mtpa and its total capacity. This expansion positions Jindal Steel as the fourth-largest steel producer in India. Supported by the incremental capacity and improving domestic demand, MOFSL expects the steelmaker to witness a 17 per cent CAGR in volume. Coupled with steady NSR growth and an increasing value-added portfolio, revenue is projected to witness a 21 per cent CAGR over FY26-28. The company has posted strong earnings in Q4FY26, and on coal gasification, this company will get benefit from coal gasification. Positive
Jindal Steel (₹ 1246.5 0.29% )
14 May 2026, 9:30AM
JSW Steel: The company reported consolidated Crude Steel production for April’26 at 21.18 Lakh tonnes. Production growth, excluding BF3 production from last year’s base, was about 10%, driven by the full ramp-up of JVML operations. The capacity utilisation of its India operations for the month stood at 83%. Neutral.
JSW Steel (₹ 1297.7 1.79% )
13 May 2026, 11:11AM
Titan: Customs duties on imports of gold, silver, platinum, and jewelry components have been increased by the government from 5% to 10%. Due to an increase in manufacturing costs, jewelry supplies will be under pressure.
Titan Company (₹ 4096 0.13% )
13 May 2026, 11:11AM
Dr Reddy’s (-ve): Total revenue from operations of the generic drugmaker was lower at Rs.7,546.4 crore (₹8,528.4 crore), according to the results prepared as per Indian Accounting Standards. Result included adverse impact of a Shelf Stock Adjustment (SSA) related to lenalidomide (generic of cancer drug Revlimid) of Rs.453 crore, impairment of CAR-T assets and Eftilagimod Alfa of a total of Rs.227.7 crore, provisions related to VAT liability of Rs.114.1 crore during the quarter. For the full year FY26, consolidated net profit of Dr. Reddy’s declined to Rs. 4,157.6 crore (Rs.5,725.2 crore). Total revenue from operations rose to Rs.33,700 crore (Rs.32,643.9 crore).
Dr Reddy's Lab (₹ 1272.5 0.57% )
13 May 2026, 11:10AM
Sri Lotus Developers : The company delivered a strong FY26 performance with pre-sales rising 137% YoY to Rs. 1,157 crore, revenue increasing 40% YoY to Rs. 769 crore, and PAT at Rs. 243 crore with healthy margins. The company remained net debt-free with gross cash of Rs. 849 crore and added nine new projects with cumulative GDV of around Rs. 8,500–9,000 crore during the year. Project Celestia in Versova saw strong traction with bookings of Rs. 155 crore within seven days of launch. For FY27, management has guided for pre-sales of Rs. 1,800–2,000 crore supported by six planned launches and continued strong demand in the luxury housing segment.
Sri Lotus Developers (₹ 140.62 -0.91% )
13 May 2026, 11:09AMTWEETS BY @Sharekhan
